Thinking about weaning off 2.5 mg Mounjaro? Here's what to consider first

Why people ask about weaning off the starter dose

A question our prescribers hear most weeks is some version of: "I've been on 2.5 mg for a few weeks and I'm wondering whether to come off it." The reasons vary considerably. Some people ask because side effects feel worse than expected. Others ask because they haven't seen much change on the scales and assume the medicine isn't working. A smaller group has a specific life event (a planned surgery, a pregnancy, or a change in circumstances) that genuinely makes stopping the right call for now.

The answer is different in each case, which is why a blanket "here's how to taper" answer doesn't serve anyone well. What the 2.5 mg dose is actually doing is training your gut to tolerate the medicine. Significant appetite reduction and weight loss typically build across the first several weeks and into the therapeutic doses above 2.5 mg. Judging whether tirzepatide is working based on the starter pen alone is a bit like deciding a course of treatment isn't effective on the first day. The 2.5 mg starting dose is the foundation, not the treatment proper.

So before framing this as "how do I wean off", it helps to identify which of three decisions actually sits in front of you: moving up the dose schedule, pausing temporarily, or stopping treatment for good. Each has a different clinical logic.

If you want to stop because of side effects at 2.5 mg

Nausea, loose stools, fatigue, and indigestion are the side effects people most often report in the first weeks of Mounjaro. They are common. They are also, for most people, at their worst in the first one to two weeks of a new dose and then settle considerably. This is well documented in the clinical trial data reviewed by NICE and the broader evidence base for tirzepatide.

Stopping because of early side effects means missing the window where tolerance develops. A prescriber may suggest a different approach: extending the time at 2.5 mg before moving up, adjusting when in the week you inject, or modifying meal size and composition around injection day. These adjustments often resolve the problem without discontinuing. If side effects are genuinely severe (particularly any persistent, severe abdominal pain) that needs urgent medical attention, not a prescription change; contact your prescriber or call 111 straight away.

If you decide, with your prescriber, that stopping is the right answer, there's no established clinical taper for tirzepatide at 2.5 mg specifically. The medicine has a relatively long half-life, so it clears gradually over several weeks after the last injection. Your prescriber will advise whether a final injection or simply not administering the next scheduled dose is the appropriate stopping point. Visit guidance on how 2.5 mg Mounjaro is taken if you have questions about the injection schedule before that conversation.

If you want to stop because you're not seeing results

At 2.5 mg, expecting measurable weight loss within the first four weeks is setting an unfair benchmark. The licensed titration schedule moves from 2.5 mg upward through 5 mg, 7.5 mg and beyond, with dose increases roughly every four weeks according to tolerability. Appetite suppression strengthens at each step. Weight outcomes in the SURMOUNT-1 trial (which studied the full dose range up to 15 mg over 72 weeks) showed average reductions of around 20% body weight at the highest dose, and you can read more about how tirzepatide 2.5 mg fits into that longer dose journey on our dedicated page. Those results come from staying the course through the titration.

If you're ready to move on to the next step, the move from 2.5 mg to 5 mg is the next clinical milestone, and your prescriber will confirm when that's appropriate based on how your body has responded. Stopping at 2.5 mg because results feel slow is nearly always premature. It is worth raising your concerns with your prescriber rather than quietly discontinuing, that conversation frequently changes the outcome.

Context on the cost of ongoing treatment matters here too. If the expense of continuing is part of the hesitation, the cost context for Mounjaro in the UK explains what drives private pricing and what a genuinely transparent service includes, which may help you assess your options more clearly.

If stopping is the right decision for you

There are legitimate reasons to stop Mounjaro, including planned pregnancy, a new contraindication identified by a clinician, surgery, or a clear shared decision that this medicine isn't the right fit. Mounjaro is not recommended during pregnancy or breastfeeding, and the prescribing guidance recommends discontinuing before trying to conceive, with appropriate contraception during treatment discussed with your clinical team. Under-18s are outside the licensed indication entirely.

When stopping, the main practical consideration is that appetite is likely to return as the medicine clears your system over the weeks following the last injection. Weight regain is a documented feature of discontinuation across GLP-1 and dual-agonist medicines, not a failure on your part. Planning for that period (including reviewing diet, activity habits, and any other support) is a conversation worth having before the last injection rather than after.

Your prescriber should also notify your GP of any change in your treatment status, in line with GPhC guidance on communication with primary care. If you sourced treatment through a registered online pharmacy, that notification process should already be part of the service. To learn more about the full range of clinically supervised weight-loss routes available through a GPhC-registered pharmacy, the treatment overview is a useful starting point. You can also find background on the clinical team at our lead prescriber's profile if you'd like to understand the clinical oversight behind online prescribing.